Collegium Pharmaceutical logo
Collegium Pharmaceutical COLL
$ 35.44 -2.37%

Annual report 2025
added 02-26-2026

report update icon

Collegium Pharmaceutical Financial Statements 2011-2026 | COLL

Annual Financial Statements Collegium Pharmaceutical

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

1.4 B 919 M 1.1 B 876 M 624 M 831 M 669 M 524 M 733 M 391 M 231 M - - - -

Shares

31.7 M 32.1 M 33.7 M 33.8 M 34.9 M 34.4 M 33.5 M 33 M 30.3 M 24.3 M 13.5 M - - - -

Historical Prices

44.2 28.6 32.5 25.9 17.9 24.1 20.1 16 23.8 16.8 17 - - - -

Net Income

17 M 12.5 M 48.2 M -25 M 71.5 M 26.8 M -22.7 M -39.1 M -74.9 M -94.2 M -27.3 M -17.9 M -16.2 M - -

Revenue

205 M 182 M 567 M 464 M 277 M 310 M 297 M 280 M 28.5 M 1.71 M - - - - -

Cost of Revenue

77.1 M 83.7 M 241 M 254 M 126 M 130 M 194 M 166 M 2.6 M 213 K - - - - -

Gross Profit

128 M 98.3 M 326 M 209 M 151 M 180 M 103 M 115 M 25.9 M 1.5 M - - - - -

Operating Income

60.8 M 38.1 M 167 M 33.3 M 17.6 M 56.2 M -23.7 M -20.7 M -75.4 M -94.1 M -26.9 M -17.7 M -16 M - -

Interest Expense

- - - - 21 M 28.9 M 909 K 20.1 M 582 K 94 K 439 K 252 K -155 K - -

EBITDA

64.9 M 42 M 170 M 36 M 19.4 M 57.1 M -8.26 M 90.2 M -74.9 M -93.4 M -26.7 M -17.5 M -15.9 M - -

Operating Expenses

67.6 M 60.2 M 159 M 176 M 133 M 124 M 127 M 135 M 101 M 95.6 M 26.9 M - - - -

General and Administrative Expenses

67.6 M 63.1 M 159 M 172 M 119 M 114 M - - - - 18.9 M 2.71 M 1.88 M - -

All numbers in USD currency

Quarterly Income Statement Collegium Pharmaceutical

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

31.6 M 31.8 M 31.8 M 31.4 M 32.3 M 32.4 M 32.3 M 31.9 M 33.7 M 34.6 M 34.3 M 33.8 M 34.1 M 34 M 33.7 M 33.7 M 35.4 M 35.3 M 35 M 34.6 M 34.5 M 34.4 M 34.1 M 33.6 M 33.5 M 33.4 M 33.3 M 33.3 M 33 M 33 M 32.9 M 32.5 M 29.8 M 29.4 M 29.4 M 27.1 M 23.5 M 23.4 M 23.1 M 20.6 M 20.5 M 11.8 M 1 M 956 K 941 K 926 K 913 K 963 K - - - - - - - - - - -

Net Income

31.5 M 12 M 2.42 M - 9.34 M 19.6 M 27.7 M - 20.6 M 13 M -17.4 M - 457 K -5.19 M -13.1 M -25 M 8.05 M 72.8 M 15.7 M 6.96 M 11.3 M 8.06 M 450 K -2.2 M -6.11 M -4.71 M -9.7 M 9.09 M -16.5 M -13.1 M -18.7 M -17.4 M -13.3 M -21.1 M -23.1 M -27.6 M -26.4 M -24.5 M -15.7 M -9.52 M -9.36 M -4.67 M -3.69 M -3.47 M -6.56 M -4.12 M -3.78 M - - - - - - - - - - - -

Revenue

209 M 188 M 178 M - 159 M 145 M 145 M - 137 M 136 M 145 M - 127 M 124 M 83.8 M 27.4 M 78.8 M 82.9 M 87.7 M 76.3 M 79.2 M 78.1 M 76.5 M 74.2 M 72.9 M 75 M 74.5 M 73.4 M 70.2 M 73.1 M 63.7 M 10.8 M 12 M 3.56 M 2.17 M - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

80.2 M 79.6 M 80.4 M - 62.5 M 54.5 M 53.5 M - 56.4 M 61.7 M 67.4 M - 68.2 M 71.2 M 35.3 M 28.7 M 32.7 M 32.7 M 32.1 M 32 M 31 M 29.7 M 37.5 M 49.1 M 46.8 M 48.7 M 49.2 M 29.7 M 46 M 46.8 M 43.1 M 1.09 M 553 K 577 K 371 K - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

129 M 108 M 97.3 M - 96.8 M 90.8 M 91.5 M - 80.3 M 73.8 M 77.4 M - 58.8 M 52.4 M 48.5 M -1.33 M 46.1 M 50.2 M 55.6 M 44.3 M 48.2 M 48.4 M 39 M 25.1 M 26.2 M 26.4 M 25.4 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

62.1 M 35.1 M 21.7 M - 34.8 M 47.5 M 49.5 M - 45 M 35.6 M 24.6 M - 20.5 M 11.1 M -10 M -34.1 M 14.1 M 16.4 M 21.2 M 15 M 19.6 M 16.5 M 5.06 M -2.37 M -6.38 M -5.01 M -9.99 M 11 M -11.2 M -7.29 M -13.2 M -17.6 M -13.4 M -21.3 M -23.2 M -27.6 M -26.4 M -24.5 M -15.6 M -9.44 M -9.26 M -4.58 M -3.63 M -3.33 M -6.5 M -4.09 M -3.74 M - - - - - - - - - - - -

Interest Expense

- - - - - - - - 20.8 M 21.9 M 21.4 M - 19 M 17.8 M 5.83 M 4.76 M 5.12 M 5.42 M 5.72 M 7.74 M 8.06 M 8.26 M 4.82 M 211 K 228 K 236 K 234 K 2.4 M 5.87 M 6.16 M 5.7 M 180 K 167 K 137 K 98 K 20 K 2 K 46 K -66 K -89 K 97 K 99 K -64 K -142 K -51 K -29 K -29 K - - - - - - - - - - - -

EBITDA

63.1 M 36.2 M 22.8 M - 35.8 M 48.4 M 50.4 M - 81.3 M 73.1 M 25.4 M - 58 M 48.6 M -9.3 M -17.3 M 15.5 M 33.2 M 21.6 M 31.8 M 20.2 M 16.9 M 5.26 M 1.32 M -5.84 M -4.65 M -9.81 M 11 M -10.5 M -6.72 M -12.7 M -17.6 M -13.4 M -21.2 M -23 M -27.6 M -26.1 M -24.4 M -15.5 M -9.44 M -9.14 M -4.48 M -3.58 M -3.33 M -6.36 M -3.99 M -3.7 M - - - - - - - - - - - -

Operating Expenses

67.1 M 73.3 M 75.6 M - 62 M 43.3 M 42 M - 35.3 M 38.2 M 52.8 M - 38.4 M 41.3 M 58.5 M 32.8 M 32 M 33.8 M 34.4 M 29.3 M 28.6 M 31.8 M 33.9 M 27.5 M 32.6 M 31.4 M 35.3 M - - - - - - - - 28.9 M 26.8 M 24.5 M 15.6 M 9.44 M 9.26 M 4.58 M 3.63 M 3.33 M 6.5 M 4.09 M 3.74 M - - - - - - - - - - - -

General and Administrative Expenses

67.1 M 73.6 M 76.4 M - 62 M 43.3 M 42 M - 35.3 M 38.2 M 52.8 M - 38.4 M 41.3 M 54.5 M 26.6 M 30.5 M 30.4 M 31.5 M 26.8 M 26.4 M 29.3 M 31.3 M 25.1 M 30.1 M 28.9 M 32.4 M 30.5 M 33.4 M 31.3 M 31.6 M 25.1 M 22.8 M 22.1 M 22.8 M 25.4 M 23.6 M 20.2 M 11.5 M 7.9 M 5.91 M 2.93 M 2.18 M 1.02 M 687 K 523 K 475 K - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Collegium Pharmaceutical COLL
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Collegium Pharmaceutical plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Assembly Biosciences Assembly Biosciences
ASMB
$ 28.46 3.45 % $ 319 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 221.88 -0.87 % $ 5 B danmarkDanmark
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 156.92 -1.23 % $ 7.81 B usaUSA
Galera Therapeutics Galera Therapeutics
GRTX
- -32.59 % $ 7.61 M usaUSA
Pharming Group N.V. Pharming Group N.V.
PHAR
$ 15.36 -0.71 % $ 7.59 B niderlandNiderland
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.37 -4.2 % $ 350 M britainBritain
Kamada Ltd. Kamada Ltd.
KMDA
$ 8.5 -1.39 % $ 260 M israelIsrael
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Benitec Biopharma Benitec Biopharma
BNTC
$ 10.98 -4.52 % $ 452 M usaUSA
Inventiva S.A. Inventiva S.A.
IVA
$ 5.78 -4.3 % $ 138 M franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Compugen Ltd. Compugen Ltd.
CGEN
$ 2.09 -0.95 % $ 195 M israelIsrael
Tiziana Life Sciences PLC Tiziana Life Sciences PLC
TLSA
$ 1.21 -3.97 % $ 71.5 M britainBritain
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
PainReform Ltd. PainReform Ltd.
PRFX
$ 2.28 -0.44 % $ 1.03 M israelIsrael
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Foghorn Therapeutics Foghorn Therapeutics
FHTX
$ 5.0 2.25 % $ 315 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.4 -3.68 % $ 1.02 B canadaCanada
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 54.13 -1.64 % $ 10.4 B usaUSA
Curis Curis
CRIS
$ 0.77 1.89 % $ 4.86 M usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.52 -5.59 % $ 178 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Burford Capital Limited Burford Capital Limited
BUR
$ 7.7 -5.87 % $ 1.29 B britainBritain
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
$ 3.34 -4.02 % $ 116 M franceFrance
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.24 -2.97 % $ 704 M canadaCanada
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
$ 1.8 -1.1 % $ 120 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Cabaletta Bio Cabaletta Bio
CABA
$ 2.94 -3.29 % $ 3.43 M usaUSA
Iterum Therapeutics Iterum Therapeutics
ITRM
$ 0.16 -5.45 % $ 3.15 M irlandaIrlanda
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA